The Association of Factor V Leiden and Prothrombin Gene Mutation and Placenta-mediated Pregnancy Complications: a Systematic Review and Meta-analysis of Prospective Cohort Studies

Overview

Journal PLoS Med

Specialty General Medicine

Date 2010 Jun 22

PMID 20563311

Citations 51

Authors

Marc A Rodger

Marisol T Betancourt

Peter Clark

Pelle G Lindqvist

Donna Dizon-Townson

Joanne Said

Uri Seligsohn

Marc Carrier

Ophira Salomon

Ian A Greer

Affiliations

Soon will be listed here.

Abstract

Background: Factor V Leiden (FVL) and prothrombin gene mutation (PGM) are common inherited thrombophilias. Retrospective studies variably suggest a link between maternal FVL/PGM and placenta-mediated pregnancy complications including pregnancy loss, small for gestational age, pre-eclampsia and placental abruption. Prospective cohort studies provide a superior methodologic design but require larger sample sizes to detect important effects. We undertook a systematic review and a meta-analysis of prospective cohort studies to estimate the association of maternal FVL or PGM carrier status and placenta-mediated pregnancy complications.

Methods And Findings: A comprehensive search strategy was run in Medline and Embase. Inclusion criteria were: (1) prospective cohort design; (2) clearly defined outcomes including one of the following: pregnancy loss, small for gestational age, pre-eclampsia or placental abruption; (3) maternal FVL or PGM carrier status; (4) sufficient data for calculation of odds ratios (ORs). We identified 322 titles, reviewed 30 articles for inclusion and exclusion criteria, and included ten studies in the meta-analysis. The odds of pregnancy loss in women with FVL (absolute risk 4.2%) was 52% higher (OR = 1.52, 95% confidence interval [CI] 1.06-2.19) as compared with women without FVL (absolute risk 3.2%). There was no significant association between FVL and pre-eclampsia (OR = 1.23, 95% CI 0.89-1.70) or between FVL and SGA (OR = 1.0, 95% CI 0.80-1.25). PGM was not associated with pre-eclampsia (OR = 1.25, 95% CI 0.79-1.99) or SGA (OR 1.25, 95% CI 0.92-1.70).

Conclusions: Women with FVL appear to be at a small absolute increased risk of late pregnancy loss. Women with FVL and PGM appear not to be at increased risk of pre-eclampsia or birth of SGA infants. Please see later in the article for the Editors' Summary.

Citing Articles

Inherited thrombophilias and stillbirth: a systematic review and meta- analysis.

Delis M, Emmanouilidou-Fotoulaki E, Chatzakis C, Theodoridis T, Sotiriadis A Arch Gynecol Obstet. 2025; .

PMID: 40087172 DOI: 10.1007/s00404-025-07989-6.

Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?.

Padrnos L, Gangaraju R Hematology Am Soc Hematol Educ Program. 2024; 2024(1):672-677.

PMID: 39643996 PMC: 11665543. DOI: 10.1182/hematology.2024000672.

A disproportionality analysis of low molecular weight heparin in the overall population and in pregnancy women using the FDA adverse event reporting system (FAERS) database.

Xu H, Xu N, Wang Y, Zou H, Wu S Front Pharmacol. 2024; 15:1442002.

PMID: 39188956 PMC: 11345143. DOI: 10.3389/fphar.2024.1442002.

Association of inherited thrombophilia mutations and their combinations among palestinian women with unexplained recurrent miscarriage.

Najjar A, Hassouna I, Srour M, Ibrahim H, Assi R, Abd El Latif H Thromb J. 2024; 22(1):20.

PMID: 38351006 PMC: 10865659. DOI: 10.1186/s12959-024-00587-7.

To Test or Not to Test: Routine Thrombophilia Diagnostic Screening of Women with Reproductive Failures.

Wysocka U, Salacinska K, Pinkier I, Kepczynski L, Alaszewski W, Dudarewicz L J Clin Med. 2023; 12(24).

PMID: 38137596 PMC: 10743545. DOI: 10.3390/jcm12247527.

References

Silver R, Zhao Y, Spong C, Sibai B, Wendel Jr G, Wenstrom K . Prothrombin gene G20210A mutation and obstetric complications. Obstet Gynecol. 2009; 115(1):14-20. PMC: 2981703. DOI: 10.1097/AOG.0b013e3181c88918. View

Kaandorp S, Goddijn M, van der Post J, Hutten B, Verhoeve H, Hamulyak K . Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med. 2010; 362(17):1586-96. DOI: 10.1056/NEJMoa1000641. View

Gris J . Thrombophilia and pregnancy loss: cause or association. Thromb Res. 2009; 123 Suppl 2:S105-10. DOI: 10.1016/S0049-3848(09)70022-2. View

Rodeghiero F, Tosetto A . The epidemiology of inherited thrombophilia: the VITA Project. Vicenza Thrombophilia and Atherosclerosis Project. Thromb Haemost. 1997; 78(1):636-40. View

Salomon O, Seligsohn U, Steinberg D, Zalel Y, Lerner A, Rosenberg N . The common prothrombotic factors in nulliparous women do not compromise blood flow in the feto-maternal circulation and are not associated with preeclampsia or intrauterine growth restriction. Am J Obstet Gynecol. 2004; 191(6):2002-9. DOI: 10.1016/j.ajog.2004.07.053. View

Dizon-Townson D, Miller C, Sibai B, Spong C, Thom E, Wendel Jr G . The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. Obstet Gynecol. 2005; 106(3):517-24. DOI: 10.1097/01.AOG.0000173986.32528.ca. View

Brenner B . Thrombophilia and adverse pregnancy outcome. Obstet Gynecol Clin North Am. 2006; 33(3):443-56, ix. DOI: 10.1016/j.ogc.2006.05.010. View

Souto J, COLL I, Llobet D, Del Rio E, Oliver A, Mateo J . The prothrombin 20210A allele is the most prevalent genetic risk factor for venous thromboembolism in the Spanish population. Thromb Haemost. 1998; 80(3):366-9. View

Bradburn M, Deeks J, Berlin J, Russell Localio A . Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2006; 26(1):53-77. DOI: 10.1002/sim.2528. View

10.

Mullan R, Flynn D, Carlberg B, Tleyjeh I, Kamath C, LaBella M . Systematic reviewers commonly contact study authors but do so with limited rigor. J Clin Epidemiol. 2008; 62(2):138-42. DOI: 10.1016/j.jclinepi.2008.08.002. View

11.

Isermann B, Sood R, Pawlinski R, Zogg M, Kalloway S, Degen J . The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med. 2003; 9(3):331-7. DOI: 10.1038/nm825. View

12.

Helewa M, Burrows R, Smith J, Williams K, Brain P, Rabkin S . Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy. CMAJ. 1997; 157(6):715-25. PMC: 1228113. View

13.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

14.

Norrie G, Farquharson R, Greaves M . Screening and treatment for heritable thrombophilia in pregnancy failure: inconsistencies among UK early pregnancy units. Br J Haematol. 2008; 144(2):241-4. DOI: 10.1111/j.1365-2141.2008.07444.x. View

15.

Howley H, Walker M, Rodger M . A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction. Am J Obstet Gynecol. 2005; 192(3):694-708. DOI: 10.1016/j.ajog.2004.09.011. View

16.

Wu O, Robertson L, Twaddle S, Lowe G, Clark P, Greaves M . Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess. 2006; 10(11):1-110. DOI: 10.3310/hta10110. View

17.

Rodger M, Paidas M, McLintock C, Claire M, Middeldorp S, Kahn S . Inherited thrombophilia and pregnancy complications revisited. Obstet Gynecol. 2008; 112(2 Pt 1):320-4. DOI: 10.1097/AOG.0b013e31817e8acc. View

18.

Clark P, Walker I, Langhorne P, Crichton L, Thomson A, Greaves M . SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood. 2010; 115(21):4162-7. DOI: 10.1182/blood-2010-01-267252. View

19.

Kraaijenhagen R, Int Anker P, Koopman M, Reitsma P, Prins M, van den Ende A . High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost. 2000; 83(1):5-9. View

20.

Koster T, Blann A, Briet E, Vandenbroucke J, Rosendaal F . Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995; 345(8943):152-5. DOI: 10.1016/s0140-6736(95)90166-3. View